KRAS mutations: Analytical considerations

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 211-220

  Herreros Villanueva, Marta ^a   Chen, Chih Chieh ^b,c   Yuan, Shyng Shiou F ^b   Liu, Ta Chih ^b,d   Er, Tze Kiong ^b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Colorectal cancer; KRAS gene; Method and mutation analysis; Mutation

Indexed keywords

RAS PROTEIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN;

BIOASSAY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COAMPLIFICATION AT LOWER DENATURATION TEMPERATURE POLYMERASE CHAIN REACTION; DENATURATION; FEASIBILITY STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC PROCEDURES; GOLD STANDARD; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MEDICAL DEVICE; MUTANT ENRICHED POLYMERASE CHAIN REACTION; MUTATION DETECTION KIT; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PEPTIDE NUCLEIC ACID CLAMP ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PYROSEQUENCING; RELIABILITY; REVIEW; SANGER SEQUENCE; SIGNAL TRANSDUCTION; COLORECTAL NEOPLASMS; GENETICS; MUTATION; ONCOGENE RAS; PERSONALIZED MEDICINE; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENES, ERBB-1; GENES, RAS; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84896819420     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.049     Document Type: Review

References (118)

1. Siegel R., DeSantis C., Virgo K., et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62:220-241.
2. Walther A., Johnstone E., Swanton C., Midgley R., Tomlinson I., Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009, 9:489-499.
3. Hoda D., Simon G.R., Garrett C.R. Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. Ther Clin Risk Manag 2008, 4:1221-1227.
4. Martinelli E., De Palma R., Orditura M., De Vita F., Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009, 158:1-9.
5. Spano J.P., Fagard R., Soria J.C., Rixe O., Khayat D., Milano G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005, 16:189-194.
6. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
7. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
8. Herreros-Villanueva M., Rodrigo M., Claver M., et al. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep 2011, 38:1315-1320.
9. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
10. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008, 19:508-515.
11. Di Fiore F., Blanchard F., Charbonnier F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169.
12. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
13. Jimeno A., Messersmith W.A., Hirsch F.R., Franklin W.A., Eckhardt S.G. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009, 27:1130-1136.
14. Chang D.Z., Kumar V., Ma Y., Li K., Kopetz S. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol 2009, 2:18.
15. Dahabreh I.J., Terasawa T., Castaldi P.J., Trikalinos T.A. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011, 154:37-49.
16. Suda K., Tomizawa K., Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010, 29:49-60.
17. Vigil D., Cherfils J., Rossman K.L., Der C.J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat Rev Cancer 2010, 10:842-857.
18. Seeburg P.H., Colby W.W., Capon D.J., Goeddel D.V., Levinson A.D. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 1984, 312:71-75.
19. Andreyev H.J., Norman A.R., Cunningham D., Oates J.R., Clarke P.A. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998, 90:675-684.
20. Malumbres M., Barbacid M. RAS oncogenes: the first 30years. Nat Rev Cancer 2003, 3:459-465.
21. Chen C.C., Er T.K., Liu Y.Y., et al. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One 2013, 8:e55793.
22. Vaughn C.P., Zobell S.D., Furtado L.V., Baker C.L., Samowitz W.S. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011, 50:307-312.
23. Loupakis F., Ruzzo A., Cremolini C., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715-721.
24. Neumann J., Zeindl-Eberhart E., Kirchner T., Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009, 205:858-862.
25. Altimari A., de Biase D., De Maglio G., et al. 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. OncoTargets Ther 2013, 6:1057-1064.
26. Gonzalez-Cadavid N.F., Zhou D., Battifora H., Bar-Eli M., Cline M.J. Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas. Oncogene 1989, 4:1137-1140.
27. Wang J., Yang H., Shen Y., et al. Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. Cancer Biomark 2013, 13:89-97.
28. Er T.K., Chang Y.S., Yeh K.T., Chang T.J., Chang J.G. Comparison of two different screening methods for the KRAS mutation in colorectal cancer. Clin Lab 2010, 56:175-186.
29. Bando I., Cillero L., Sanz-Ortega J., et al. Study of KRAS new predictive marker in a clinical laboratory. Clin Transl Oncol 2012, 14:937-942.
30. Domagala P., Hybiak J., Sulzyc-Bielicka V., Cybulski C., Rys J., Domagala W. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach. Pol J Pathol 2012, 63:145-164.
31. Evaluation of Genomic Applications in P, Prevention Working G. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?. Genet Med 2013, 15:517-527.
32. Anderson S.M. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn 2011, 11:635-642.
33. Lewandowska M.A., Jozwicki W., Zurawski B. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. Mol Diagn Ther 2013, 17:193-203.
34. Clayton S.J., Scott F.M., Walker J., et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem 2000, 46:1929-1938.
35. Thelwell N., Millington S., Solinas A., Booth J., Brown T. Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res 2000, 28:3752-3761.
36. Angulo B., Garcia-Garcia E., Martinez R., et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 2010, 12:292-299.
37. Miglio U., Mezzapelle R., Paganotti A., et al. Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. Pathol Res Pract 2013, 209:233-236.
38. Gonzalez de Castro D., Angulo B., Gomez B., et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer 2012, 107:345-351.
39. Harle A., Busser B., Rouyer M., et al. Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. Virchows Arch 2013, 462:329-335.
40. Kotoula V., Charalambous E., Biesmans B., et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 2009, 4:e7746.
41. Nordgard O., Oltedal S., Janssen E.A., et al. Comparison of a PNA clamp PCR and an ARMS/Scorpion PCR assay for the detection of K-ras mutations. Diagn Mol Pathol 2012, 21:9-13.
42. Hancer V.S., Buyukdogan M., Turkmen I., et al. Comparison of KRAS mutation tests in colorectal cancer patients. Genet Test Mol Biomarkers 2011, 15:831-834.
43. Whitehall V., Tran K., Umapathy A., et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009, 11:543-552.
44. Ogasawara N., Bando H., Kawamoto Y., et al. Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers. Jpn J Clin Oncol 2011, 41:52-56.
45. Prix L., Uciechowski P., Bockmann B., Giesing M., Schuetz A.J. Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool. Clin Chem 2002, 48:428-435.
46. Thiede C., Bayerdorffer E., Blasczyk R., Wittig B., Neubauer A. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 1996, 24:983-984.
47. Ausch C., Buxhofer-Ausch V., Oberkanins C., et al. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. J Mol Diagn 2009, 11:508-513.
48. Farina Sarasqueta A., Moerland E., de Bruyne H., et al. SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics. J Mol Diagn 2011, 13:199-205.
49. Cavallini A., Valentini A.M., Lippolis C., Campanella D., Guerra V., Caruso M.L. KRAS genotyping as biomarker in colorectal cancer: a comparison of three commercial kits on histologic material. Anticancer Res 2010, 30:5251-5256.
50. Herreros-Villanueva M., Aggarwal G. KRAS assay selection: sensitivity and accuracy in clinical application. Mol Biol Rep 2012, 39:2467-2470.
51. Graham R., Liew M., Meadows C., Lyon E., Wittwer C.T. Distinguishing different DNA heterozygotes by high-resolution melting. Clin Chem 2005, 51:1295-1298.
52. Takano E.A., Mitchell G., Fox S.B., Dobrovic A. Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer 2008, 8:59.
53. Simi L., Pratesi N., Vignoli M., et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008, 130:247-253.
54. Krypuy M., Newnham G.M., Thomas D.M., Conron M., Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006, 6:295.
55. Malapelle U., Carlomagno C., Salatiello M., et al. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer 2012, 107:626-631.
56. Akiyoshi K., Yamada Y., Honma Y., et al. KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing. Anticancer Res 2013, 33:2129-2134.
57. Deschoolmeester V., Boeckx C., Baay M., et al. KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer 2010, 103:1627-1636.
58. Ney J.T., Froehner S., Roesler A., Buettner R., Merkelbach-Bruse S. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. Arch Pathol Lab Med 2012, 136:983-992.
59. Ma E.S., Wong C.L., Law F.B., Chan W.K., Siu D. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J Clin Pathol 2009, 62:886-891.
60. Li B.S., Wang X.Y., Xu A.G., et al. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA Test for the detection of mutations in colorectal neoplasms. Clin Colorectal Cancer 2012, 11:280-290.
61. Fadhil W., Ibrahem S., Seth R., et al. The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. Histopathology 2012, 61:1117-1124.
62. Ibrahem S., Seth R., O'Sullivan B., Fadhil W., Taniere P., Ilyas M. Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection. Int J Exp Pathol 2010, 91:500-505.
63. He C., Zheng L., Xu Y., Liu M., Li Y., Xu J. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer. Clin Chim Acta 2013, 425:119-124.
64. Bearzatto A., Conte D., Frattini M., et al. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 2002, 8:3782-3787.
65. Asano H., Toyooka S., Tokumo M., et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006, 12:43-48.
66. Molinari F., Felicioni L., Buscarino M., et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 2011, 17:4901-4914.
67. Milbury C.A., Li J., Liu P., Makrigiorgos G.M. COLD-PCR: improving the sensitivity of molecular diagnostics assays. Expert Rev Mol Diagn 2011, 11:159-169.
68. Song C., Milbury C.A., Li J., Liu P., Zhao M., Makrigiorgos G.M. Rapid and sensitive detection of KRAS mutation after fast-COLD-PCR enrichment and high-resolution melting analysis. Diagn Mol Pathol 2011, 20:81-89.
69. Milbury C.A., Correll M., Quackenbush J., Rubio R., Makrigiorgos G.M. COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing. Clin Chem 2012, 58:580-589.
70. Li J., Wang L., Janne P.A., Makrigiorgos G.M. Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. Clin Chem 2009, 55:748-756.
71. Milbury C.A., Li J., Makrigiorgos G.M. PCR-based methods for the enrichment of minority alleles and mutations. Clin Chem 2009, 55:632-640.
72. Kristensen L.S., Daugaard I.L., Christensen M., Hamilton-Dutoit S., Hager H., Hansen L.L. Increased sensitivity of KRAS mutation detection by high-resolution melting analysis of COLD-PCR products. Hum Mutat 2010, 31:1366-1373.
73. How Kit A., Mazaleyrat N., Daunay A., Nielsen H.M., Terris B., Tost J. Sensitive detection of KRAS mutations using enhanced-ice-COLD-PCR mutation enrichment and direct sequence identification. Hum Mutat 2013, 34:1568-1580.
74. Orum H., Nielsen P.E., Egholm M., Berg R.H., Buchardt O., Stanley C. Single base pair mutation analysis by PNA directed PCR clamping. Nucleic Acids Res 1993, 21:5332-5336.
75. Luo J.D., Chan E.C., Shih C.L., et al. Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res 2006, 34:e12.
76. Karkare S., Bhatnagar D. Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino. Appl Microbiol Biotechnol 2006, 71:575-586.
77. Oh J.E., Lim H.S., An C.H., et al. Detection of low-level KRAS mutations using PNA-mediated asymmetric PCR clamping and melting curve analysis with unlabeled probes. J Mol Diagn 2010, 12:418-424.
78. Yu S., Xiao X., Lu J., Qian X., Liu B., Feng J. Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy. PLoS One 2013, 8:e68022.
79. Yu S., Wu J., Xu S., Tan G., Liu B., Feng J. Modified PNA-PCR method: a convenient and accurate method to screen plasma KRAS mutations of cancer patients. Cancer Biol Ther 2012, 13:314-320.
80. Kobunai T., Watanabe T., Yamamoto Y., Eshima K. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun 2010, 395:158-162.
81. Kwon M.J., Lee S.E., Kang S.Y., Choi Y.L. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract 2011, 207:762-768.
82. Fakhrai-Rad H., Pourmand N., Ronaghi M. Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat 2002, 19:479-485.
83. Chen D.C., Saarela J., Nuotio I., Jokiaho A., Peltonen L., Palotie A. Comparison of GenFlex Tag array and pyrosequencing in SNP genotyping. J Mol Diagn 2003, 5:243-249.
84. Jordan J.A., Butchko A.R., Durso M.B. Use of pyrosequencing of 16S rRNA fragments to differentiate between bacteria responsible for neonatal sepsis. J Mol Diagn 2005, 7:105-110.
85. Ogino S., Kawasaki T., Brahmandam M., et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005, 7:413-421.
86. Sundstrom M., Edlund K., Lindell M., et al. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer 2010, 10:660.
87. Poehlmann A., Kuester D., Meyer F., Lippert H., Roessner A., Schneider-Stock R. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 2007, 203:489-497.
88. Dufort S., Richard M.J., de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 2009, 391:166-168.
89. Shen S., Qin D. Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. Diagn Pathol 2012, 7:56.
90. Pourmand N., Elahi E., Davis R.W., Ronaghi M. Multiplex Pyrosequencing. Nucleic Acids Res 2002, 30:e31.
91. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
92. Andre T., Blons H., Mabro M., et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol 2013, 24:412-419.
93. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
94. Rizzo S., Bronte G., Fanale D., et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treat Rev 2010, 36(Suppl. 3):S56-S61.
95. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261.
96. De Roock W., Biesmans B., De Schutter J., Tejpar S. Clinical biomarkers in oncology: focus on colorectal cancer. Mol Diagn Ther 2009, 13:103-114.
97. Perkins G., Lievre A., Ramacci C., et al. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Int J Cancer 2010, 127:1321-1331.
98. Sood A., McClain D., Maitra R., et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 2012, 11:143-150.
99. Van Cutsem E., Kohne C.H., Lang I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
100. Farina-Sarasqueta A., van Lijnschoten G., Moerland E., et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010, 21:2396-2402.
101. Yokota T., Ura T., Shibata N., et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011, 104:856-862.
102. Ogino S., Lochhead P., Giovannucci E., Meyerhardt J.A., Fuchs C.S., Chan A.T. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene 2013 Jun 24, [Epub ahead of print]. 10.1038/onc.2013.244.
103. Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369:1023-1034.
104. Peeters M., Oliner K.S., Parker A., et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013, 19:1902-1912.
105. Han S.W., Kim H.P., Shin J.Y., et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One 2013, 8:e64271.
106. Morozova O., Marra M.A. Applications of next-generation sequencing technologies in functional genomics. Genomics 2008, 92:255-264.
107. Bras J., Guerreiro R., Hardy J. Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. Nat Rev Neurosci 2012, 13:453-464.
108. Metzker M.L. Sequencing technologies-the next generation. Nat Rev Genet 2010, 11:31-46.
109. Ross J.S. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective. Arch Pathol Lab Med 2012, 136:1298-1307.
110. Ludyga N., Grunwald B., Azimzadeh O., et al. Nucleic acids from long-term preserved FFPE tissues are suitable for downstream analyses. Virchows Arch 2012, 460:131-140.
111. Okello J.B., Zurek J., Devault A.M., et al. Comparison of methods in the recovery of nucleic acids from archival formalin-fixed paraffin-embedded autopsy tissues. Anal Biochem 2010, 400:110-117.
112. Turashvili G., Yang W., McKinney S., et al. Nucleic acid quantity and quality from paraffin blocks: defining optimal fixation, processing and DNA/RNA extraction techniques. Exp Mol Pathol 2012, 92:33-43.
113. Bonin S., Hlubek F., Benhattar J., et al. Multicentre validation study of nucleic acids extraction from FFPE tissues. Virchows Arch 2010, 457:309-317.
114. Jennings L., Van Deerlin V.M., Gulley M.L. College of American Pathologists Molecular Pathology Resource C. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med 2009, 133:743-755.
115. Raymaekers M., Smets R., Maes B., Cartuyvels R. Checklist for optimization and validation of real-time PCR assays. J Clin Lab Anal 2009, 23:145-151.
116. Mattocks C.J., Morris M.A., Matthijs G., et al. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet 2010, 18:1276-1288.
117. Burd E.M. Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev 2010, 23:550-576.
118. Wooley J.C., Godzik A., Friedberg I. A primer on metagenomics. PLoS Comput Biol 2010, 6:e1000667.